The Psyres Fund aims to support scientific research of substances that carry a potential for mental health. Our goal is to inform the general public of past, current and planned research activities in the field of psychedelic substances and to encourage the growing interest in these substances by disseminating information based on scientific evidence.
There is already evidence supporting the possibility of direct therapeutic use of certain psychedelics such as ketamine, psilocybin, LSD and MDMA in the treatment of depression, posttraumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and other conditions.
Over the last decade, there have been several studies on the use of psychedelics in palliative care, reducing anxiety and depressive symptoms, and coping with the onset of death.
The current categorization of psychedelics among drugs with no medical use and high risk of addiction not only potentially stigmatizes these therapeutic tools, but are also places a bureaucratic and financial burden on the researchers themselves. By providing financial resources, you can contribute not only to the development of mental health science, but at the same time reduce the need for administrative burdens associated with securing funding for reputable domestic research in this area.
Mental illnesses are a major problem in the 21st century. Every fourth person experiences some form of mental illness during their life (WHO). Up to 40% of those suffering are not getting effective help. Patients who are resistant to existing forms of treatment would get a chance of a cure through new approaches.
The Czech Republic has been active in psychedelic research since the 1960s and 1970s. After the prohibition was eventually lifted on the use of psychedelic substances in research, Tomáš Páleníček is once again performing important research activities as the leader of an entire research team. At present, research at the National Institute of Mental Health is conducted on psilocybin (healthy volunteers) and ketamine (in resistant depression), and the phenomenology of 5-MeO-DMT. Over the next few, it is planned to support two worldwide clinical trials, namely: 1) the use of psilocybin in the treatment of drug-resistant depression (Compass), and 2) MDMA in the treatment of post-traumatic stress disorder (MAPS). An increasing interest in neuroscientists is also devoted to DMT (the component Ayahuasca), which is the only psychedelic naturally occurring in the human brain. At present, we are in negotiations with a chief of an Indian tribe in Brazil, where our scientists hope to visit on a research expedition devoted to studying ayahuasca activity.
A first research study has already been supported by Václav Dejčmar through the Psychedelic Research Fund. This study focuses on the micro-dosing of psilocybin and ketamine in an animal model.
We have significantly advanced in many areas of human knowledge over the last century. This also applies to our knowledge of the functioning of the human brain in times of physical and mental illness. By contributing to the Psychedelic Research Fund, you can help to shift this knowledge further into the community of supporters.
The PSYRES Psychedelic Research fund was established by Společnost pro podporu neurovědního výzkumu s.r.o. (Company for the Support of Neurological Research).
The main aim of the endowment fund is to support research teams and workplaces focussing on the study of psychedelic substances. Primarily, the fund is dedicated to supporting studies in the areas of pharmacology, neurobiology, primary and secondary prevention of their hazardous use, psychology, addictology and psychiatry, which focus on the mechanisms of the psychotropic effects of these substances. In a wider context, the fund also supports social science projects directed at the cultural consequences and history of the use of psychedelics.
Primarily, the fund is geared to support the team research from the National Institute of Mental Health, but it is also open to applications for support for other workplaces in the Czech Republic and Slovakia, in which the National Institute of Mental Health figures as a co-researcher.